24/7 Market News Snapshot 15 July, 2025 – 60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP)

July 15, 2025

DENVER, Colo., 15 July, 2025 (www.247marketnews.com) – (NASDAQ:SXTP) are discussed in this article.
In an energizing pre-market trading session, 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) has reported a notable increase in its stock price, now at $3.112, a significant rise of approximately 43.74% from its previous closing value of $2.165. The surge is marked by an impressive trading volume of 7.56 million shares, reflecting heightened investor enthusiasm and strong market sentiment surrounding the company.

Simultaneously, 60 Degrees Pharmaceuticals has made significant strides in the treatment of human babesiosis with its innovative product, ARAKODA® (tafenoquine). The firm has identified a potential market for ARAKODA® that encompasses around 380,000 patients, suggesting an annual sales opportunity of approximately $245 million. Furthermore, during the product’s patent lifecycle, ending in 2035, the cumulative market potential could surpass 1.17 million patients, translating to an estimated $1.1 billion.

Human babesiosis, often prevalent as a co-infection alongside Lyme Disease, presents a pressing medical challenge, particularly given the absence of FDA-approved treatments to combat this tick-borne illness. This underscores the importance of 60 Degrees Pharmaceuticals’ commitment to enhancing patient care in this critical area.

Dr. Geoff Dow, Chief Executive Officer, commented on the company’s extensive market analysis, which included a nationwide survey of 6,000 patients and insights from 300 healthcare professionals, emphasizing the transformative potential of ARAKODA® in improving treatment outcomes. The company is focused on advancing its clinical program, with a New Drug Application (NDA) submission anticipated in 2026.

With three clinical trials currently in progress to assess the safety and efficacy of ARAKODA®, data is expected in the first half of 2026, which will be vital for the NDA submission to the U.S. Food and Drug Administration. Through these initiatives, 60 Degrees Pharmaceuticals aims to deliver impactful solutions for infectious diseases and improve the quality of life for those affected by human babesiosis.

Related news for (SXTP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.